Sign inJoin waitlistJoin the waitlist

Daniel Laheru

Advisor for Solid Tumors · Johns Hopkins University School of Medicine

Credentials: · · ·

History

Johns Hopkins University School of Medicine
Present

Medical Oncology
1998–2000
Internal Medicine
1995–1998
Baylor College of Medicine
1991–1995

Research

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 7,710 citations
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
New England Journal of Medicine · 2013 · 5,446 citations
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Science · 2017 · 5,443 citations

JH
Joseph Herman
74 papers
Christopher Wolfgang
73 papers
Lei Zheng
67 papers
Elizabeth Jaffee
66 papers
Ralph Hruban
59 papers
DL
Dung Le
55 papers
JC
John Cameron
42 papers
AJ
Ana De Jesus-Acosta
39 papers
Ross Donehower
37 papers
JH
Jin He
36 papers · 3 as a fellow
Timothy Pawlik
35 papers
Amol Narang
32 papers · 4 as a resident

Grants

Gene Modified Vaccine in Combination with Ipilimumab for Advanced Pancreatic Canc
National Cancer Institute · R21
Contact PI · $661.1K · Johns Hopkins University
2008–2012
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $564 · Johns Hopkins University
2006–2007
Gene Modified Cell Lines as Vaccine for Pancreas Cancer
National Cancer Institute · K23
Contact PI · $684.5K · Johns Hopkins University
2002–2007

Clinical trials

Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Principal investigator · Completed · Phase 1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2018–2021
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
Principal investigator · Completed · Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2018–2024
Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Principal investigator · Terminated · Phase 1
Washington University School of Medicine
2018–2022
Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
Principal investigator · Completed · Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2012–2023